- June 13, 2019 Spero Announces $10 Million Registered Direct Offering of Common Stock
- May 31, 2019 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 09, 2019 Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
- May 01, 2019 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- April 08, 2019 Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- March 29, 2019 Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
- March 19, 2019 Spero Announces Appointment of Cynthia Smith to its Board of Directors
- March 14, 2019 Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review
- March 01, 2019 Spero Therapeutics to Present at March Investor Conferences
- February 26, 2019 Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720
Displaying 1 - 10 of 14 results